Cargando…
Vaccines
Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vacci...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120629/ http://dx.doi.org/10.1007/978-1-4614-9164-4_17 |
_version_ | 1783515016281980928 |
---|---|
author | Perrie, Yvonne Kaur, Randip Henriksen-Lacey, Malou |
author_facet | Perrie, Yvonne Kaur, Randip Henriksen-Lacey, Malou |
author_sort | Perrie, Yvonne |
collection | PubMed |
description | Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations. |
format | Online Article Text |
id | pubmed-7120629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71206292020-04-06 Vaccines Perrie, Yvonne Kaur, Randip Henriksen-Lacey, Malou Fundamentals of Pharmaceutical Nanoscience Article Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations. 2013-10-17 /pmc/articles/PMC7120629/ http://dx.doi.org/10.1007/978-1-4614-9164-4_17 Text en © Springer Science+Business Media New York 2013 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Perrie, Yvonne Kaur, Randip Henriksen-Lacey, Malou Vaccines |
title | Vaccines |
title_full | Vaccines |
title_fullStr | Vaccines |
title_full_unstemmed | Vaccines |
title_short | Vaccines |
title_sort | vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120629/ http://dx.doi.org/10.1007/978-1-4614-9164-4_17 |
work_keys_str_mv | AT perrieyvonne vaccines AT kaurrandip vaccines AT henriksenlaceymalou vaccines |